Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib + PD-0325901 in KRAS-mutant metastatic non-small cell lung cancer
NL-OMON47225Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dacomitinib and mirdametinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Apr 2014; status: active, not recruiting.
02
Drugs
dacomitinibmirdametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47225.